Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-vpsfw Total loading time: 0 Render date: 2024-07-18T21:20:32.909Z Has data issue: false hasContentIssue false

51 - EBV: Immunobiology and host response

from Part III - Pathogenesis, clinical disease, host response, and epidemiology: gammaherpesviruses

Published online by Cambridge University Press:  24 December 2009

By
Denis J. Moss ,
Scott R. Burrows  and
Rajiv Khanna
Edited by
Ann Arvin ,
Gabriella Campadelli-Fiume ,
Edward Mocarski ,
Patrick S. Moore ,
Bernard Roizman ,
Richard Whitley  and
Koichi Yamanishi
Denis J. Moss
Affiliation:
Infectious Disease and Immunology Division, Queensland Institute of Medical Research and Joint Oncology Program, University of Queensland, Australia
Scott R. Burrows
Affiliation:
Infectious Disease and Immunology Division, Queensland Institute of Medical Research and Joint Oncology Program, University of Queensland, Australia
Rajiv Khanna
Affiliation:
Infectious Disease and Immunology Division, Queensland Institute of Medical Research and Joint Oncology Program, University of Queensland, Australia
Ann Arvin
Affiliation:
Stanford University, California
Gabriella Campadelli-Fiume
Affiliation:
Università degli Studi, Bologna, Italy
Edward Mocarski
Affiliation:
Emory University, Atlanta
Patrick S. Moore
Affiliation:
University of Pittsburgh
Bernard Roizman
Affiliation:
University of Chicago
Richard Whitley
Affiliation:
University of Alabama, Birmingham
Koichi Yamanishi
Affiliation:
University of Osaka, Japan
Get access

Summary

Introduction

The biology and immunology of Epstein–Barr virus (EBV) has continued to fascinate researchers because the lessons learnt provide a platform for understanding the interplay between the biology of this ubiquitous infection, the immune system seeking to restrict its spread and the emergence of a variety of malignancies. As with other gamma herpes viruses, EBV encodes a large set of lytic cycle genes together with a number of latent genes which are associated with expansion of the latent EBV pool in B-lymphocytes. Current evidence suggests that the virus gains entry into the body by infection of B-lymphocytes in the oral cavity via an interaction between the major viral glycoprotein gp340 and the complement receptor CR2 which is expressed on B-cells, although a role for CR2-expressing or non-expressing epithelial and/or T-cells cannot be totally discounted. In either case, evidence suggests that the earliest detectable event following primary infection is the expression of lytic cycle proteins resulting in the release of infectious virus into the oral cavity followed by a generalized seeding of latently infected B-lymphocytes throughout the body. This primary infection results in symptoms of acute infectious mononucleosis (IM) in about 50% of adolescents and is coincident with a marked lymphocytosis (dominated by EBV-specific cytotoxic T-cells) and the appearance of an IgM response to a variety of EBV proteins, most notably the viral capsid antigen, VCA.

Type
Chapter
Information
Human Herpesviruses
Biology, Therapy, and Immunoprophylaxis
 , pp. 904 - 914
Publisher: Cambridge University Press
Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Annels, N. E., Callan, M. F., Tan, L., and Rickinson, A. B. (2000). Changing patterns of dominant TCR usage with maturation of an EBV-specific cytotoxic T cell response. J. Immunol., 165, 4831–4841.CrossRefGoogle ScholarPubMed
Bejarano, M. T. and Massuci, M. G. (1998). Interleukin-10 abrogates the inhibition of Epstein–Barr virus-induced B-cell transformation by memory T-cell responses. Blood, 92, 4256–4262.Google ScholarPubMed
Bharadwaj, M., Parsons, P. G., and Moss, D. J. (2001). Cost-efficient quantification of enzyme-linked immunospot. Biotechniques, 30, 36–38.Google ScholarPubMed
Bishop, C. J., Moss, D. J., Ryan, J. M., and Burrows, S. R. (1985). T lymphocytes in infectious mononucleosis. II. Response in vitro to interleukin-2 and establishment of T-cell lines. Clin. Exp. Immunol., 60, 70–77.Google ScholarPubMed
Brion, A., Cahn, J. Y., Mougin, C.et al. (1995). Herpes virus-related lymphoproliferative disorders following allogeneic bone marrow transplantation: clinical and biological characteristics of six cases. Nouv. Rev. Fr. Hematol., 37, 289–296.Google ScholarPubMed
Brooks, J. M., Murray, R. J., Thomas, W. A., Kurilla, M. G., and Rickinson, A. B. (1993). Different HLA-B27 subtypes present the same immunodominant Epstein–Barr virus peptide. J. Exp. Med., 178, 879–887.CrossRefGoogle ScholarPubMed
Burrows, S. R., Khanna, R., Burrows, J. M., and Moss, D. J. (1994). An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein–Barr virus CTL epitope: implications for graft-versus-host disease. J. Exp. Med., 179, 1155–1161.CrossRefGoogle ScholarPubMed
Burrows, S. R., Silins, S. L., Moss, D. J., Khanna, R., Misko, I. S., and Argaet, V. P. (1995). T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J. Exp. Med., 182, 1703–1715.CrossRefGoogle ScholarPubMed
Burrows, S. R., Elkington, R. A., Miles, J. J.et al. (2003). Promiscuous CTL recognition of viral epitopes on multiple human leukocyte antigens: biological validation of the proposed HLA A24 supertype. J. Immunol., 171, 1407–1412.CrossRefGoogle ScholarPubMed
Callan, M. F. (2003). The evolution of antigen-specific CD8+ T cell responses after natural primary infection of humans with Epstein–Barr virus. Viral Immunol., 16, 3–16.CrossRefGoogle ScholarPubMed
Callan, M. F., Steven, N., Krausa, P.et al. (1996). Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat. Med., 2, 906–911.CrossRefGoogle ScholarPubMed
Callan, M. F., Tan, L., Annels, N.et al. (1998). Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein–Barr virus In vivo. J. Exp. Med. 187, 1395–1402.CrossRefGoogle ScholarPubMed
Callan, M. F., Fazou, C., Yang, H.et al. (2000). CD8(+) T-cell selection, function, and death in the primary immuneresponse in vivo. J. Clin. Invest., 106, 1251–1261.CrossRefGoogle Scholar
Cohen, J. I. (1999). The biology of Epstein–Barr virus:lessons learned from the virus and the host. Curr. Opin. Immunol.. 11, 365–370.CrossRefGoogle Scholar
Cohen, J. I. and Lekstrom, K. (1999). Epstein–Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells. J. Virol., 73, 7627–7632.Google ScholarPubMed
Couedel, C., Bodinier, M., Peyrat, M. A., Bonneville, M., Davodeau, F., and Lang, F. (1999). Selection and long-term persistence of reactive CTL clones during an EBV chronic response are determined by avidity, CD8 variable contribution compensating for differences in TCR affinities. J. Immunol., 162, 6351–6358.Google ScholarPubMed
Dukers, D. F., Meij, P., and Vervoort, M. B. (2000). Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. J. Immunol., 165, 663–670.CrossRefGoogle ScholarPubMed
Gregory, C. D., Kirchgens, C., Edwards, C. F.et al. (1987). Epstein–Barr virus-transformed human precursor B cell lines: altered growth phenotype of lines with germ-line or rearranged but nonexpressed heavy chain genes. Eur. J. Immunol., 17, 1199–1207.Google ScholarPubMed
Hislop, A. D., Gudgeon, N. H., Callan, M. F.et al. (2001). EBV-specific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. J. Immunol., 167, 2019–2029.CrossRefGoogle ScholarPubMed
Hislop, A. D., Annels, N. E., Gudgeon, N. H., Leese, A. M., and Rickinson, A. B. (2002). Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein–Barr virus infection. J. Exp. Med., 195, 893–905.CrossRefGoogle ScholarPubMed
Jones, R. J., Smith, L. J., Dawson, C. W., Haigh, T., Blake, N. W., and Young, L. S. (2003). Epstein–Barr virus nuclear antigen 1 (EBNA1) induced cytotoxicity in epithelial cells is associated with EBNA1 degradation and processing. Virology, 313, 663–676.CrossRefGoogle Scholar
Khanna, R. (1998). Tumour surveillance: missing peptides and MHC molecules. Immunol. Cell Biol., 76, 20–26.CrossRefGoogle ScholarPubMed
Khanna, R. and Burrows, S. R. (2000). Role of cytotoxic t lymphocytes in epstein–barr virus-associated diseases. Annu. Rev. Microbiol., 54, 19–48.CrossRefGoogle ScholarPubMed
Khanna, R., Burrows, S. R., Argaet, V., and Moss, D. J. (1994). Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int. Immunol., 6, 639–645.CrossRefGoogle ScholarPubMed
Khanna, R., Rowe, M., Jacob, C. A.et al. (1995). Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein–Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur. J. Immunol., 25, 1374–1384.Google Scholar
Khanna, R., Burrows, S. R., Moss, D. J., and Silins, S. L. (1996). Peptide transporter (TAP1 and TAP-2)-independent endogenous processing of Epstein–Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies. J. Virol., 70, 5357–5362.Google ScholarPubMed
Khanna, R., Burrows, S. R., Thomson, S. A.et al. (1997). class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs. J. Immunol., 158, 3619–3625.Google Scholar
Khanna, R., Busson, P., Burrows, S. R.et al. (1998). Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein–Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res., 58, 310–314.Google ScholarPubMed
Kjer-Nielsen, L., Clements, C. S., Purcell, A. W.et al. (2003). A structural basis for the selection of dominant alphabeta T cell receptors in antiviral immunity. Immunity, 18, 53–64.CrossRefGoogle ScholarPubMed
Lautscham, G., Haigh, T., Mayrhofer, S.et al. (2003). Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein–Barr virus latent membrane protein 2. J. Virol., 77, 2757–2761.CrossRefGoogle ScholarPubMed
Lee, S. P., Thomas, W. A., Blake, N. W., and Rickinson, A. B. (1996). Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein–Barr virus latent membrane protein 2. Eur. J. Immunol., 26, 1875–1883.CrossRefGoogle ScholarPubMed
Lee, S. P., Constandinou, C. M., Thomas, W. A.et al. (1998). Antigen presenting phenotype of hodgkin reed-sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein–Barr virus-specific cytotoxic T-cell recognition [In Process Citation]. Blood, 92, 1020–1030.Google Scholar
Leen, A., Meij, P., Redchenko, I.et al. (2001). Differential immunogenicity of Epstein–Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J. Virol., 75, 8649–8659.CrossRefGoogle ScholarPubMed
Levitskaya, J., Coram, M., Levitsky, V.et al. (1995). Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1. Nature, 375, 685–688.CrossRefGoogle ScholarPubMed
Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A., and Masucci, M. G. (1997). Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein–Barr virus nuclear antigen 1. Proc. Natl Acad. Sci. USA, 94, 12616–12621.CrossRefGoogle ScholarPubMed
Li, Q., Spriggs, M. K., Kovats, S.et al. (1997). Epstein–Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J. Virol., 71, 4657–4662.Google ScholarPubMed
Marshall, N. A., Vickers, M. A., and Barker, R. N. (2003). Regulatory T cells secreting IL10 dominate the immune response to EBV latent membrane protein 1. J. Immunol., 170, 6183–6189.CrossRefGoogle ScholarPubMed
Miles, J. J., Elhassen, D., Borg, N. A., et al. (2005). CTL recognition of a bulged viral peptide involves biased TCR selection. J. Immunol., 175, 3826–3834.CrossRefGoogle ScholarPubMed
Moore, K. W., Vieira, P., Fiorentino, D. F., Trounstine, M. L., Khan, T. A., and Mosmann, T. R. (1990). Homology of cytokine synthesis inhibitory factor (IL-10) to theEpstein–Barr virus gene BCRF1. Science, 248, 1230–1234.CrossRefGoogle Scholar
Moss, D. J., Burrows, S. R., Castelino, D. J., Kane, R. G., Pope, J. H., and Rickinson, A. B. (1983). A comparison of Epstein–Barr virus-specific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea. Int. J. Cancer, 31, 727–732.CrossRefGoogle ScholarPubMed
Moss, D. J., Bishop, C. J., Burrows, S. R., and Ryan, J. M. (1985). T lymphocytes in infectious mononucleosis. I. T-cell death in vitro. Clin. Exp. Immunol., 60, 61–69.Google ScholarPubMed
Muller, A., Schmitt, L., Raftery, M., and Schönrich, G. (1998). Paralysis of B7 co-stimulation through the effect of viral IL-10 on T cells as a mechanism of local tolerance induction. Eur. J. Immunol., 28, 3488–3498.3.0.CO;2-Y>CrossRefGoogle Scholar
Munz, C., Bickham, K. L., and Subklewe, M. (2000). Human CD4(+) T lymphocytes consistently respond to the latent Epstein–Barr virus nuclear antigen EBNA1. J. Exp. Med., 191, 1649–1660.CrossRefGoogle ScholarPubMed
Pai, S. and Khanna, R. (2002). Role of LMP1 in immune control of EBV infection. Semin. Cancer Biol., 11, 455–460.CrossRefGoogle Scholar
Paludan, C., Bickham, K., Nikiforow, S.et al. (2002). Epstein–Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J. Immunol., 169, 1593–1603.CrossRefGoogle ScholarPubMed
Precopio, M. L., Sullivan, J. L., Willard, C., Somasundaran, M., and Luzuriaga, K. (2003). Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection. J. Immunol., 170, 2590–2598.CrossRefGoogle ScholarPubMed
Reedman, B. M., Hilgers, J., Hilgers, F., and Klein, G. (1975). Immunofluorescence and anti-complement immunofluorescence absorption tests for quantitation of Epstein–Barr virus-associated antigens. Int. J. Cancer, 15, 566–571.CrossRefGoogle ScholarPubMed
Ressing, M. E., Keating, S. E., Leeuwen, D.et al. (2005). Impaired transporter associated with antigen processing-dependent protein transport during productive EBV infection. J. Immunol., 174, 6829–6838.CrossRefGoogle ScholarPubMed
Rickinson, A. B. and Kieff, E. (1996). Epstein–Barr virus. In Fields Virology. Fields, B. N., Knipe, D. M., and Howley, P. M., eds., pp. 2397–2446. Philadelphia: Lippincott-Raven Publishers.Google Scholar
Rooney, C. M., Smith, C. A., Ng, C.et al. (1995). Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus-related lymphoproliferation. Lancet, 345, 9–13.CrossRefGoogle ScholarPubMed
Sallusto, F., Lenig, D., Forster, R., Lipp, M., and Lanzavecchia, A. (1999). Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature, 401, 708–712.CrossRefGoogle ScholarPubMed
Schmidt, C. W. and Misko, I. S. (1995). The ecology and pathology of Epstein–Barr virus. Immunol. Cell Biol., 73, 489–504.CrossRefGoogle ScholarPubMed
Sherritt, M. A., Bharadwaj, M., Burrows, J. M.et al. (2003). Reconstitution of the latent T-lymphocyte response to Epstein–Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation, 75, 1556–1560.CrossRefGoogle ScholarPubMed
Silins, S. L., Cross, S. M., Elliott, S. L.et al. (1996). Development of Epstein–Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis. J. Exp. Med., 184, 1815–1824.CrossRefGoogle ScholarPubMed
Silins, S. L., Cross, S. M., Elliott, S. L.et al. (1997). Selection of a diverse TCR repertoire in response to an Epstein- Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection. Int. Immunol., 9, 1745–1755.CrossRefGoogle Scholar
Silins, S. L., Cross, S. M., Krauer, K. G., Moss, D. J., Schmidt, C. W., and Misko, I. S. (1998). A functional link for major TCR expansions in healthy adults caused by persistent Epstein–Barr virus infection. J. Clin. Invest., 102, 1551–1558.CrossRefGoogle ScholarPubMed
Silins, S. L., Sherritt, M. A., Silleri, J. M.et al. (2001). Asymptomatic primary Epstein–Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood, 98, 3739–3744.CrossRefGoogle ScholarPubMed
Slivnick, D. J., Ellis, T. M., Nawrocki, J. F., and Fisher, R. I. (1990). The impact of Hodgkin's disease on the immune system. Semin. Oncol, 17, 673–682.Google ScholarPubMed
Spear, P. G. and Longnecker, R. (2003). Herpesvirus entry: an update. J. Virol., 77, 10179–10185.CrossRefGoogle ScholarPubMed
Spriggs, M. K., Armitage, R. J., Comeau, M. R.et al. (1996). The extracellular domain of the Epstein–Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation. J. Virol., 70, 5557–5563.Google ScholarPubMed
Steven, N. M., Leese, A. M., Annels, N. E., Lee, S. P., and Rickinson, A. B. (1996) Epitope focusing in the primary cytotoxic T cell response to Epstein–Barr virus and its relationship to T cell memory. J. Exp. Med. 184, 1801–1813.CrossRefGoogle ScholarPubMed
Strockbine, L. D., Cohen, J. I., Farrah, T.et al. (1998). The Epstein–Barr virus BARF1 gene encodes a novel, soluble colony-stimulating factor-1 receptor. J. Virol., 72, 4015–4021.Google ScholarPubMed
Takaoka, A., Hayakawa, S., Yanai, H.et al. (2003). Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature, 424, 516–523.CrossRefGoogle ScholarPubMed
Tellam, J., Connolloy, G., Green, K. J.et al. (2004). Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus encoded nuclear antigen 1: functional evidence for DriPs as a source of endogenously processed epitopes. J. Exp. Med., 199, 1421–1431.CrossRefGoogle Scholar
Topalian, S. L., Rivoltini, L., Mancini, M., Ng, J., Hartzman, R. J., and Rosenberg, S. A. (1994). Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein–Barr virus- transformed B cells. Int. J. Cancer, 58, 69–79.CrossRefGoogle ScholarPubMed
Uchida, J., Yasui, T., Takaoka-Shichijo, Y.et al. (1999). Mimicry of CD40 signals by Epstein–Barr virus LMP1 in B lymphocyte responses. Science, 286, 300–303.CrossRefGoogle ScholarPubMed
Voo, K. S., Fu, T.Wang, H. Y.et al. (2004). Evidence for the presentation of major histocompatibility complex class irestricted Epstein–Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J. Exp. Med., 199, 459–470.CrossRefGoogle Scholar
Yin, Y., Manoury, B., and Fahraeus, R. (2003). Self-inhibition of synthesis and antigen presentation by Epstein–Barr virus-encoded EBNA1. Science, 301, 1371–1374.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • EBV: Immunobiology and host response
    • By Denis J. Moss, Infectious Disease and Immunology Division, Queensland Institute of Medical Research and Joint Oncology Program, University of Queensland, Australia, Scott R. Burrows, Infectious Disease and Immunology Division, Queensland Institute of Medical Research and Joint Oncology Program, University of Queensland, Australia, Rajiv Khanna, Infectious Disease and Immunology Division, Queensland Institute of Medical Research and Joint Oncology Program, University of Queensland, Australia
  • Edited by Ann Arvin, Stanford University, California, Gabriella Campadelli-Fiume, Università degli Studi, Bologna, Italy, Edward Mocarski, Emory University, Atlanta, Patrick S. Moore, University of Pittsburgh, Bernard Roizman, University of Chicago, Richard Whitley, University of Alabama, Birmingham, Koichi Yamanishi, University of Osaka, Japan
  • Book: Human Herpesviruses
  • Online publication: 24 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545313.052
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • EBV: Immunobiology and host response
    • By Denis J. Moss, Infectious Disease and Immunology Division, Queensland Institute of Medical Research and Joint Oncology Program, University of Queensland, Australia, Scott R. Burrows, Infectious Disease and Immunology Division, Queensland Institute of Medical Research and Joint Oncology Program, University of Queensland, Australia, Rajiv Khanna, Infectious Disease and Immunology Division, Queensland Institute of Medical Research and Joint Oncology Program, University of Queensland, Australia
  • Edited by Ann Arvin, Stanford University, California, Gabriella Campadelli-Fiume, Università degli Studi, Bologna, Italy, Edward Mocarski, Emory University, Atlanta, Patrick S. Moore, University of Pittsburgh, Bernard Roizman, University of Chicago, Richard Whitley, University of Alabama, Birmingham, Koichi Yamanishi, University of Osaka, Japan
  • Book: Human Herpesviruses
  • Online publication: 24 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545313.052
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • EBV: Immunobiology and host response
    • By Denis J. Moss, Infectious Disease and Immunology Division, Queensland Institute of Medical Research and Joint Oncology Program, University of Queensland, Australia, Scott R. Burrows, Infectious Disease and Immunology Division, Queensland Institute of Medical Research and Joint Oncology Program, University of Queensland, Australia, Rajiv Khanna, Infectious Disease and Immunology Division, Queensland Institute of Medical Research and Joint Oncology Program, University of Queensland, Australia
  • Edited by Ann Arvin, Stanford University, California, Gabriella Campadelli-Fiume, Università degli Studi, Bologna, Italy, Edward Mocarski, Emory University, Atlanta, Patrick S. Moore, University of Pittsburgh, Bernard Roizman, University of Chicago, Richard Whitley, University of Alabama, Birmingham, Koichi Yamanishi, University of Osaka, Japan
  • Book: Human Herpesviruses
  • Online publication: 24 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545313.052
Available formats
×